Noteworthy Tuesday Option Activity: STX, HCA, TXN

HCA Healthcare saw options volume of 5,849 contracts (≈584,900 underlying shares), about 64% of its one‑month average daily volume (913,870), with notable activity in the $430 put expiring Feb 20, 2026 (1,367 contracts ≈136,700 shares). Texas Instruments registered 39,097 option contracts (≈3.9M underlying shares), roughly 58.2% of its one‑month ADV (6.7M), led by the $220 call expiring Feb 20, 2026 (7,742 contracts ≈774,200 shares); such concentrated activity represents significant positioning and warrants monitoring for potential flow-driven price impact.

Analysis

Market structure: The concentrated LEAP activity (HCA 1,367 Feb-2026 puts ≈136.7k shares; TXN 7,742 Feb-2026 calls ≈774.2k shares) signals sizeable directional bets by institutions or structured-product desks rather than retail. Direct beneficiaries: market-makers, option sellers collecting premium and hedging flows; TXN stands to gain from positive AI/industrial capex narratives, HCA put buyers suggest concern about utilization/reimbursement risk. The notional equals ~58–64% of each name’s 30‑day ADV, implying potential multi-week rebalancing flows as deltas change, which can move equities without immediate news.

Risk assessment: Tail risks include a negative reimbursement/regulatory shock to HCA (Medicare cuts or state rate changes) and a semiconductor demand shock for TXN (inventory correction or soft AI capex). Time horizons separate: immediate (days-weeks) price moves from delta-hedging; medium (3–6 months) driven by earnings/guide; long (12+ months) tied to secular chip cycle and healthcare utilization. Hidden dependencies: flows may be part of structured notes hedging (gamma exposures), creating non-linear liquidity needs; IV compression of >20% would punish option buyers. Key catalysts: TXN earnings/capex commentary (next 60–90 days), HCA volume/earnings and any CMS policy moves in next 3–6 months.

Trade implications: For TXN, prefer directional exposure via bought call spreads (Feb-2026 $220/$280) sized 1–3% portfolio to capture upside while capping premium; if IV rises >25% consider selling short-dated calls against core position. For HCA, consider asymmetric protection: buy Feb-2026 $430/$380 bear put spread (cost-defined) or short 0.5–1% equity with tight 12–15% stop; avoid naked short puts given potential skew. Cross-sector pair: long TXN, short HCA to express secular tech tailwinds vs healthcare utilization risk, target 2:1 notional skew in favor of TXN.

Contrarian angles: The market may be misreading LEAP flow as pure directional bets—flows could be hedges or positive-delta structures (buy-write synthetics) that will reverse when issued products reprice. Reaction could be overdone: if HCA fundamentals remain stable, IV could collapse and provide opportunity to sell verticals for income (target IV >30%). Conversely, crowded long-TXN LEAP positioning could amplify downside on any AI capex disappointment; set portfolio stress test of 20–30% drawdown scenario on TXN and size accordingly.

Key Decisions for Investors

• Establish a 1.5–3% portfolio long position in TXN via Feb-2026 $220/$280 call spreads (buy $220, sell $280) to limit premium; enter within 2–6 weeks, target realized upside >30% if TXN outperforms, cut if TXN equity falls >15% within 30 days or IV drops >25%.
• Establish a 0.5–1% portfolio bearish sleeve on HCA via Feb-2026 $430/$380 bear put spreads (limit risk) OR short 0.5% equity with a 12–15% stop-loss; size smaller due to regulatory tail risk and tighten if CMS guidance is supportive within 90 days.
• Implement a relative-value pair trade: long TXN (1.5%) vs short HCA (0.75%) to express tech secular vs healthcare demand risk; rebalance monthly and close or reduce 50% exposure if combined position moves >20% against within 45 days.
• If HCA implied volatility rises above 30% without material negative fundamentals in 30 days, sell 3–6 month out-of-the-money put spreads (e.g., sell $420/$380) for income, max one-half percent portfolio risk per spread, to harvest premium from skew.
• Monitor catalysts: TXN earnings/capex commentary and HCA CMS/state reimbursement headlines over next 60–90 days; if either stock gaps >10% on news, reassess and trim option exposure by 50% within 5 trading days.